American Mask Manufacturer s Association Launches, Aims For Closer Ties With Government, Federal Agencies
News provided by
Share this article
WASHINGTON, April 29, 2021 /PRNewswire/ The American Mask Manufacturers Association (
AMMA) today is proud to announce its official formation, with the goal of eliminating foreign dependence on PPE by increasing production, procurement and distribution of American-made face masks, saving American lives, and driving manufacturing growth. AMMA appreciates the steps taken by the Biden administration and Capitol Hill with the recently enacted American Rescue Plan and related Executive Orders and look forward to working with them to further define a clear path towards creating a cycle of security, opportunity, and prosperity.
Ceribell Announces Completion Of $53 Million Series C Financing
Proceeds will be used to expand commercialization of the Ceribell Rapid Response EEG and support pipeline product development to drive future clinical applications
News provided by
Share this article
MOUNTAIN VIEW, Calif., April 29, 2021 /PRNewswire/
Ceribell, Inc., innovator of the Rapid Response EEG™, a novel non-invasive brain monitor, announced today the completion of a $53 million Series C financing, co-led by Longitude Capital and The Rise Fund. Other new investors include RA Capital Management, Redmile Group and Red Tree Venture Capital, with additional support from existing shareholders.
The Ceribell® technology platform is designed to address the need for faster diagnosis in patients with suspicion of seizure. The company will use financing proceeds to further expand Ceribell s commercial footprint in emergency departments and intensive care units globally. In addition, Ceribell will continue to
Share this article
Share this article
LONGMONT, Colo., April 28, 2021 /PRNewswire/ KromaTiD is pleased to announce that BroadOak Capital Partners has made an investment in the Company. KromaTiD s sales and operations are rapidly accelerating, driven by growing market adoption of their products and services, such as the recently launched dGH In-Site™ and dGH SCREEN™ products for gene editing and gene therapy applications. This capital will be used to accelerate commercialization, support ongoing product development, and to increase capacity to meet growing demand.
KromaTiD s directional Genomic Hybridization™, or dGH™, today provides the genomic structural context necessary to optimize gene editing strategies for research and clinical purposes, such as therapeutic gene editing based on CRISPR technologies, requiring measurements that can only be made with a single cell, genome-wide analysis provided by dGH™.
Strongest order intake in Mentice s history despite the corona pandemic
First quarter (January-March 2021)
Order book by end of the period was 72.9 (33.9) MSEK.
Net sales amounted to 32.3 (33.8) MSEK.
Operating income for the period before depreciations (EBITDA) totalled
-8.4 (-0,5) MSEK.
Earnings per share (EPS) was -0.50 (-0.21) SEK.
Cash flow from operating activities totalled -13.1 (1.5) MSEK.
CEO Göran Malmberg comments: Continued strong order intake, with the strongest order intake figure for a first quarter in Mentice s history on the back end of our strongest order intake for a fourth quarter ever (2020). Our net sales for the first quarter plus order book scheduled for 2021 is at 38% above the level from the same time last year. Net sales for the quarter slightly below last year s number due to deliveries being postponed due to the pandemic.
Caresyntax Raises $100 Million to Make Surgery Smarter and Safer
Investment will strengthen technology and expand company s reach
News provided by
Share this article
Share this article
BOSTON, April 28, 2021 /PRNewswire/ Caresyntax, the leading enterprise-level digital surgery platform delivering actionable insights to make surgery smarter and safer, today announced that it has closed a $100 million Series C funding round led by PFM Health Sciences LP, and included participation from Optum Ventures, Intel Capital, Lauxera Capital Partners, Vesalius Biocapital III, Arno Capital, Rezayat Investments, as well as current investors IPF Partners, the Relyens Group, and Surgical.AI. The investment follows a year in which the company saw 250% growth in new contract value, supported more than 30,000 surgeons, and improved care for more than two million patients.